Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of LSALT peptide in Covid-19 hospitalized patients at risk to inflammation in the lungs, kidneys or liver

Next Previous
X
Search
Trial Profile

Phase 3 trial of LSALT peptide in Covid-19 hospitalized patients at risk to inflammation in the lungs, kidneys or liver

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metablok-Arch Biopartners (Primary)
  • Indications Acute kidney injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia; Inflammation; Liver disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Arch Biopartners

    • Most Recent Events

    • 23 Mar 2023 According to an Arch Biopartners media release, company receives funding support from NRC IRAP to continue development of LSALT Peptide as a treatment for inflammation injury in the lungs, kidneys, and liver. This project funding will enable Arch to complete several important drug development tasks in the next 12 month.
    • 18 Aug 2020 According to an Arch Biopartners media release, the phase II results will be used to design a phase III registration trial, including higher patient numbers and optimal drug dosing.
    • 06 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top